Back to Search Start Over

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

Authors :
Michele Aieta
Alessandra Perin
Alfredo Berruti
Luca S Burgio
Marcello Tucci
Caterina Messina
Giovanni Mansueto
Maurizio Nicodemo
Ugo De Giorgi
Gilbert Spizzo
Cinzia Ortega
Francesca Maines
Paolo Andrea Zucali
Orazio Caffo
Giuseppe Di Lorenzo
Francesco Massari
Antonello Veccia
Andrea Bonetti
Giovanni Lo Re
Gaetano Facchini
Vittorina Zagonel
Daniele Alesini
Alessandro D'Angelo
Roberto Bortolus
Maddalena Donini
Michele Lodde
Giovanni Vicario
Umberto Basso
Daniele Santini
Rodolfo Mattioli
Enzo Galligioni
Florinda Scognamiglio
Giuseppe Procopio
Claudia Mucciarini
Teodoro Sava
Lucia Fratino
Source :
Future Oncology. 12:493-502
Publication Year :
2016
Publisher :
Future Medicine Ltd, 2016.

Abstract

Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre- and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3–4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.

Details

ISSN :
17448301 and 14796694
Volume :
12
Database :
OpenAIRE
Journal :
Future Oncology
Accession number :
edsair.doi.dedup.....cec974fcf83835ad5eb6c8f8406e9519
Full Text :
https://doi.org/10.2217/fon.15.302